Grifols, S.A. (GIFLF) Aktienanalyse
Nur zu Informationszwecken. Keine Finanzberatung. Analysis by Sedat Aydin, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Grifols, S.A. (GIFLF) ist im Healthcare-Sektor taetig, zuletzt notiert bei $ mit einer Marktkapitalisierung von 0. Die Aktie erzielt 52/100, eine moderate Bewertung basierend auf 9 quantitativen KPIs.
Zuletzt analysiert: 17. März 2026Grifols, S.A. (GIFLF) Gesundheitswesen & Pipeline-Uebersicht
Grifols, S.A., founded in 1940 and headquartered in Barcelona, is a global healthcare leader focused on plasma-derived therapies and diagnostic solutions. Operating across Bioscience, Hospital, Diagnostic, and Bio Supplies divisions, Grifols serves diverse healthcare needs, addressing chronic, rare, and life-threatening diseases with a comprehensive portfolio of products and services.
Investmentthese
Grifols, S.A. presents a notable research candidate within the healthcare sector, driven by its leading position in plasma-derived therapies and diagnostic solutions. The company's consistent profitability, demonstrated by a 5.3% profit margin and 38.4% gross margin, underscores its operational efficiency. A key value driver is the increasing demand for plasma-derived products, fueled by an aging global population and advancements in medical treatments. Upcoming catalysts include the potential expansion of its product portfolio and geographic reach. However, investors should be aware of potential risks, including regulatory changes and competition from other players in the industry. Grifols' beta of 1.19 suggests a slightly higher volatility compared to the market, while its dividend yield of 1.60% provides a steady income stream for investors.
Basierend auf FMP-Finanzdaten und quantitativer Analyse
Wichtige Highlights
- Market capitalization of $8.78 billion reflects Grifols' significant presence in the healthcare industry.
- P/E ratio of 16.01 indicates a reasonable valuation compared to its earnings.
- Profit margin of 5.3% demonstrates the company's ability to generate profit from its revenue.
- Gross margin of 38.4% highlights the efficiency of Grifols' production and sales processes.
- Dividend yield of 1.60% provides a steady income stream for investors.
Wettbewerber & Vergleichsunternehmen
Staerken
- Leading position in plasma-derived therapies.
- Diversified product portfolio.
- Global presence and distribution network.
- Strong R&D capabilities.
Schwaechen
- Dependence on plasma supply.
- Exposure to regulatory changes.
- High R&D costs.
- Competition from other players in the industry.
Katalysatoren
- Ongoing: Increasing demand for plasma-derived therapies due to the aging global population.
- Ongoing: Expansion of the company's product portfolio through R&D efforts.
- Upcoming: Potential strategic acquisitions to expand market share.
- Upcoming: Positive clinical trial results for new therapies in development.
- Ongoing: Geographic expansion into emerging markets with high growth potential.
Risiken
- Potential: Fluctuations in plasma prices could impact profitability.
- Ongoing: Intense competition from other players in the plasma-derived therapies market.
- Potential: Regulatory changes could impact the company's operations and financial performance.
- Potential: Product liability claims could result in significant financial losses.
- Ongoing: Economic downturns could reduce demand for the company's products and services.
Wachstumschancen
- Expansion of Bioscience Division: Grifols can expand its Bioscience division by developing new plasma-derived therapies and increasing its market share in existing products. The global market for immunoglobulins, for example, is projected to reach $18.5 billion by 2028, presenting a significant growth opportunity for Grifols. This expansion can be achieved through increased R&D investment and strategic acquisitions.
- Geographic Expansion: Grifols has the opportunity to expand its geographic presence, particularly in emerging markets. These markets offer significant growth potential due to increasing healthcare spending and a growing demand for plasma-derived therapies. The company can leverage its existing infrastructure and partnerships to penetrate these markets effectively.
- Diagnostic Division Growth: The Diagnostic division can drive growth by developing and commercializing innovative diagnostic products that address unmet medical needs. The global market for diagnostic products is expected to grow at a CAGR of 5% over the next five years, driven by advancements in technology and increasing demand for personalized medicine. Grifols can capitalize on this trend by investing in R&D and strategic partnerships.
- Hospital Division Expansion: Grifols can expand its Hospital division by offering a wider range of non-biological pharmaceutical products, medical supplies, and medical devices. The global market for hospital supplies is projected to reach $45 billion by 2027, presenting a significant growth opportunity for Grifols. This expansion can be achieved through strategic acquisitions and partnerships.
- Bio Supplies Division Growth: The Bio Supplies division can drive growth by providing biological materials for life-science research, clinical trials, and manufacturing pharmaceutical and diagnostic products. The increasing demand for these materials, driven by advancements in biotechnology and personalized medicine, presents a significant growth opportunity for Grifols. The company can leverage its expertise and infrastructure to capitalize on this trend.
Chancen
- Expansion into emerging markets.
- Development of new plasma-derived therapies.
- Growth in the diagnostic products market.
- Strategic acquisitions and partnerships.
Risiken
- Fluctuations in plasma prices.
- Increased competition.
- Product liability claims.
- Economic downturns.
Wettbewerbsvorteile
- Specialized expertise in plasma-derived therapies.
- Extensive network of plasma donation centers.
- Strong relationships with healthcare providers and institutions.
- Proprietary manufacturing processes and technologies.
Ueber GIFLF
Founded in 1940 in Barcelona, Spain, Grifols, S.A. has evolved into a global healthcare company specializing in plasma-derived therapies and diagnostic solutions. The company operates through four primary divisions: Bioscience, Hospital, Diagnostic, and Bio Supplies. The Bioscience division is the core of Grifols' business, focusing on the research, development, production, and marketing of plasma-derived medicines. These therapies include immunoglobulins, alpha-1 antitrypsin, albumin, clotting factors, and hyperimmune globulins, which are used to treat patients with chronic, rare, prevalent, and life-threatening diseases. The Hospital division provides non-biological pharmaceutical products, medical supplies, clinical nutrition products, intravenous therapy solutions, and medical devices. The Diagnostic division develops and commercializes diagnostic products used across the healthcare continuum, from prevention and screening to diagnosis, prognosis, and treatment monitoring. The Bio Supplies division offers biological materials for life-science research, clinical trials, and manufacturing pharmaceutical and diagnostic products. Grifols serves a wide range of customers, including public and private healthcare providers, wholesalers, distributors, group purchasing organizations, blood banks, hospitals, care institutions, and national health systems. The company has a technology collaboration agreement with Mondragon, further enhancing its innovation capabilities. With a global presence and a commitment to innovation, Grifols is dedicated to improving patient outcomes and advancing healthcare worldwide.
Was das Unternehmen tut
- Procures plasma from donors.
- Manufactures therapeutic products from plasma.
- Develops and commercializes diagnostic products.
- Offers non-biological pharmaceutical products and medical supplies.
- Provides biological materials for life-science research.
- Markets plasma-derived medicines to treat chronic, rare, and life-threatening diseases.
Geschaeftsmodell
- Generates revenue from the sale of plasma-derived therapies.
- Earns revenue from the sale of diagnostic products and services.
- Profits from the sale of hospital supplies and medical devices.
- Derives income from providing biological materials for research and manufacturing.
Branchenkontext
Grifols operates in the drug manufacturing industry, which is characterized by intense competition, stringent regulatory requirements, and high research and development costs. The global market for plasma-derived therapies is experiencing steady growth, driven by the increasing prevalence of chronic diseases and advancements in medical technology. Grifols competes with other major players in the industry, including BDUUF (B. Braun Melsungen AG), CSPCY (CSL Limited), ESAIY (Eisai Co., Ltd.), ESALF (EssilorLuxottica SA), and KYKOF (Kyowa Kirin Co., Ltd.). The company's focus on innovation and strategic partnerships positions it favorably within this competitive landscape.
Wichtige Kunden
- Public and private healthcare providers
- Wholesalers and distributors
- Blood banks and hospitals
- National health systems
Finanzdaten
Chart & Info
Grifols, S.A. (GIFLF) Aktienkurs: Price data unavailable
Aktuelle Nachrichten
Keine aktuellen Nachrichten fuer GIFLF verfuegbar.
Analystenkonsens
Konsens-Bewertung
Aggregierte Kauf-/Halten-/Verkauf-Empfehlungen von Benzinga, Yahoo Finance und Finnhub fuer GIFLF.
Kursziele
Wall-Street-Kurszielanalyse fuer GIFLF.
MoonshotScore
Was bedeutet diese Bewertung?
Der MoonshotScore bewertet das Wachstumspotenzial von GIFLF auf einer Skala von 0-100 ueber mehrere Faktoren wie Innovation, Marktdisruption, finanzielle Gesundheit und Momentum.
Fuehrung: Jose Ignacio Abia Buenache
CEO
Jose Ignacio Abia Buenache serves as the CEO of Grifols, S.A., leading a global workforce of 23,833 employees. His career history reflects a deep understanding of the healthcare industry, with extensive experience in strategic management and operational leadership. He is responsible for guiding Grifols' overall strategy, driving innovation, and ensuring the company's continued growth and success in the global market. His leadership is crucial in navigating the complexities of the plasma-derived therapies and diagnostic solutions sectors.
Erfolgsbilanz: Under Jose Ignacio Abia Buenache's leadership, Grifols has continued to expand its global presence and strengthen its position as a leader in plasma-derived therapies. Key achievements include strategic acquisitions, the development of innovative products, and the expansion of the company's R&D capabilities. His focus on operational efficiency and strategic partnerships has contributed to Grifols' consistent profitability and growth.
GIFLF OTC-Marktinformationen
The OTC Other tier represents the lowest tier of the OTC market, encompassing securities that are not eligible for trading on OTCQX or OTCQB. Companies in this tier often have limited or no financial disclosure, making it difficult for investors to assess their financial health and operational performance. Unlike companies listed on major exchanges like the NYSE or NASDAQ, OTC Other companies are not subject to stringent listing requirements or regulatory oversight, which increases the risk for investors.
- OTC-Stufe: OTC Other
- Offenlegungsstatus: Unknown
- Limited financial disclosure increases the risk of investing in GIFLF.
- Lower trading volume and wider bid-ask spreads can lead to price volatility.
- Lack of regulatory oversight increases the potential for fraud or mismanagement.
- The OTC market is generally more susceptible to market manipulation.
- Delays in trade execution due to lower liquidity.
- Verify the company's registration and regulatory filings.
- Review any available financial statements and disclosures.
- Assess the company's business model and competitive landscape.
- Evaluate the management team's experience and track record.
- Monitor trading volume and price volatility.
- Understand the risks associated with investing in OTC stocks.
- Consult with a financial advisor before investing.
- Grifols, S.A. is a well-established company with a long operating history.
- The company has a global presence and serves a wide range of customers.
- Grifols is a leader in the plasma-derived therapies market.
- The company has a technology collaboration agreement with Mondragon.
- The company employs over 23,000 employees.
Haeufige Fragen zu GIFLF
What are the key factors to evaluate for GIFLF?
Grifols, S.A. (GIFLF) currently holds an AI score of 52/100, indicating moderate score. Key strength: Leading position in plasma-derived therapies.. Primary risk to monitor: Potential: Fluctuations in plasma prices could impact profitability.. This is not financial advice.
How frequently does GIFLF data refresh on this page?
GIFLF prices update in real time during U.S. market hours (9:30 AM-4:00 PM ET, weekdays). Fundamentals refresh after quarterly or annual filings. Analyst ratings and AI insights update daily. News is aggregated continuously from financial sources.
What has driven GIFLF's recent stock price performance?
Recent price movement in Grifols, S.A. (GIFLF) can be influenced by earnings results, analyst revisions, sector rotation, and broader market sentiment. Notable catalyst: Leading position in plasma-derived therapies.. Check the News and Technical Analysis tabs for the latest drivers. Past performance does not predict future results.
Should investors consider GIFLF overvalued or undervalued right now?
Determining whether Grifols, S.A. (GIFLF) is overvalued or undervalued requires examining multiple metrics. Compare valuation ratios (P/E, P/S, EV/EBITDA) against sector peers for a comprehensive view.
What research should beginners do before buying GIFLF?
Before investing in Grifols, S.A. (GIFLF), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Why might investors consider adding GIFLF to a portfolio?
Potential reasons to consider Grifols, S.A. (GIFLF) depend on individual investment goals and risk tolerance. A key strength identified by analysis: Leading position in plasma-derived therapies.. Additionally: Diversified product portfolio.. Always weigh potential rewards against risks and diversify across holdings. This is not financial advice.
Can I buy fractional shares of GIFLF?
Yes, most major brokerages offer fractional shares of Grifols, S.A. (GIFLF) with no minimum purchase requirement. This means you can invest any dollar amount regardless of the share price. Check your brokerage platform for specific terms, fees, and fractional share availability.
How can I track GIFLF's earnings and financial reports?
Grifols, S.A. (GIFLF) reports quarterly earnings approximately 4-6 weeks after each fiscal quarter ends. You can track earnings dates, revenue and EPS estimates, and actual results on this page's Financials tab. Earnings surprises (beats or misses) often cause significant short-term price moves. Setting up alerts through your brokerage for GIFLF earnings announcements is recommended.
Haftungsausschluss: Dieser Inhalt dient ausschliesslich zu Informationszwecken und stellt keine Anlageberatung dar. Fuehren Sie immer Ihre eigene Recherche durch und konsultieren Sie einen Finanzberater.
Offizielle Ressourcen
Daten dienen ausschliesslich zu Informationszwecken.
- OTC data may be less reliable than exchange-listed data.
- AI analysis is pending and may provide additional insights.